Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Clinipace Worldwide has entered into a definitive merger agreement with Swiss-based PFC Pharma Focus (PFC) under which it has acquired all outstanding shares of PFC and its subsidiaries.
Subscribe to our email newsletter
PFC is a pan-European contract research provider focused on drug and medical device development services and regulatory consulting.
The combination of PFC and Clinipace Worldwide is expected to create a digital clinical research organization (dCRO) with centralized North American, South American, and European hubs for strategic drug and medical device product development, clinical operations, data management, regulatory affairs, and GxP/CMC quality assurance.
Clinipace Worldwide CEO and chairman Jeff Williams said with this acquisition they have assembled the right global footprint and the right mix of global therapeutic expertise, strategic product development assets and operational capabilities to meet the needs of their clients.
"Together with the PFC team we’re better positioned to serve the needs of our clients by scaling to support their global phase 2-3 trials across a number of therapeutic areas and indications," Williams said.
PFC was co-founded by Kurt Pfister and Kathryn Voegeli in 1992.
Kurt joined as an executive team of European operations as CEO and Kathryn joined as COO.
Jeff Williams will remain the CEO and chairman of the combined company.